Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

Core Viewpoint - Rapt Therapeutics (RAPT) shares have seen a 1.7% increase over the past four weeks, closing at $7.84, with analysts suggesting a potential upside of 282.7% based on a mean price target of $30 [1] Price Targets and Estimates - The average price target for RAPT ranges from a low of $8.00 to a high of $48.00, with a standard deviation of $21.04, indicating variability in analyst estimates [2] - The lowest estimate suggests a 2% increase from the current price, while the highest estimate indicates a potential upside of 512.2% [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about RAPT's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 22.6% rise in the Zacks Consensus Estimate for the current year [12] - RAPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of RAPT's potential gains, the direction implied by these targets appears to be a useful guide for investors [14]